Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has scheduled its first quarter 2025 earnings release and business updates for May 13, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss developments, financial results, and future outlook. Investors can access the live audio webcast through the company's investor relations website at investors.absci.com, where a replay will also be available after the event.
Absci (Nasdaq: ABSI), un'azienda che utilizza l'intelligenza artificiale generativa basata sui dati per la creazione di farmaci, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e gli aggiornamenti aziendali per il 13 maggio 2025, dopo la chiusura dei mercati. L'azienda terrà una conference call e una webcast alle 16:30 ora della costa orientale (13:30 ora della costa pacifica) per discutere gli sviluppi, i risultati finanziari e le prospettive future. Gli investitori potranno seguire la diretta audio streaming attraverso il sito web delle relazioni con gli investitori all'indirizzo investors.absci.com, dove sarà disponibile anche la registrazione dopo l'evento.
Absci (Nasdaq: ABSI), una empresa de creación de fármacos basada en inteligencia artificial generativa y centrada en datos, ha programado la publicación de sus resultados del primer trimestre de 2025 y actualizaciones comerciales para el 13 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. hora del Este (1:30 p.m. hora del Pacífico) para discutir avances, resultados financieros y perspectivas futuras. Los inversores podrán acceder a la transmisión de audio en vivo a través del sitio web de relaciones con inversores en investors.absci.com, donde también estará disponible la grabación después del evento.
Absci (나스닥: ABSI)는 데이터 중심의 생성형 AI 신약 개발 회사로, 2025년 1분기 실적 발표 및 사업 업데이트를 2025년 5월 13일 장 마감 후에 예정하고 있습니다. 회사는 동부 표준시 오후 4시 30분(태평양 표준시 오후 1시 30분)에 컨퍼런스 콜과 웹캐스트를 개최하여 개발 현황, 재무 결과 및 향후 전망에 대해 논의할 예정입니다. 투자자들은 회사 투자자 관계 웹사이트인 investors.absci.com을 통해 라이브 오디오 웹캐스트에 접속할 수 있으며, 행사 후에는 다시보기 서비스도 제공됩니다.
Absci (Nasdaq : ABSI), une société de création de médicaments basée sur l'IA générative et axée sur les données, a programmé la publication de ses résultats du premier trimestre 2025 et des mises à jour commerciales pour le 13 mai 2025, après la clôture des marchés. L'entreprise organisera une conférence téléphonique et une webdiffusion à 16h30 heure de l'Est (13h30 heure du Pacifique) pour discuter des développements, des résultats financiers et des perspectives futures. Les investisseurs pourront accéder à la diffusion audio en direct via le site web des relations investisseurs à investors.absci.com, où une rediffusion sera également disponible après l'événement.
Absci (Nasdaq: ABSI), ein datenorientiertes Unternehmen für generative KI-basierte Arzneimittelentwicklung, hat die Veröffentlichung der Quartalsergebnisse für das erste Quartal 2025 sowie Geschäftsaktualisierungen für den 13. Mai 2025 nach Börsenschluss angekündigt. Das Unternehmen wird um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time) eine Telefonkonferenz und einen Webcast abhalten, um Entwicklungen, Finanzergebnisse und zukünftige Aussichten zu besprechen. Investoren können den Live-Audio-Webcast über die Investor-Relations-Website des Unternehmens unter investors.absci.com verfolgen, wo auch eine Aufzeichnung nach der Veranstaltung zur Verfügung stehen wird.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When will Absci (ABSI) release its Q1 2025 earnings?
What time is Absci's (ABSI) Q1 2025 earnings call?
Where can I listen to Absci's (ABSI) Q1 2025 earnings webcast?
Will there be a replay available for Absci's (ABSI) Q1 2025 earnings call?
